Werewolf Therapeutics reports Q1 net loss of $16.2M; cash runway extended to Q1 2026

Werewolf Therapeutics, Inc.

2024-Q1 EPS reported -$0.39

Net loss $16.2M in Q1 2024, up from $12.0M loss in Q1 2023; R&D expenses rose to $12.9M.
Cash and equivalents $139.2M at March 31, 2024; new $60M loan from K2 HealthVentures ($30M drawn) extends runway through Q1 2026.
Collaboration revenue from Jazz Pharma fell to $0.7M from $4.5M YoY.
Planned ASCO 2024 presentation of WTX-124 combination dose-escalation data; Q2 interim data for WTX-330 monotherapy.
Preclinical advances: WTX-518 and WTX-712 show tumor regressions in mouse models; IL-10 for IBD presented at AAI.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Werewolf Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $0.7 million.

Period: first quarter ended March 31, 2024
Revenue: $0.7 million
Result: reported results

Exact text from the filing

be sufficient to fund operational expenses and capital expenditure requirements through at least the first quarter of 2026. • Collaboration revenue: Collaboration revenue was $0.7 million for the first quarter of 2024, compared to $4.5 million for the same period in 2023. Collaboration revenue consists of revenue recognized from the Company’s licensing agreement

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Werewolf Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001785530-24-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.